Mark Tidswell to Follow-Up Studies
This is a "connection" page, showing publications Mark Tidswell has written about Follow-Up Studies.
Connection Strength
0.087
-
Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 2010 Jan; 38(1):72-83.
Score: 0.059
-
Lanspa MJ, Gong MN, Schoenfeld DA, Lee KT, Grissom CK, Hou PC, Serpa-Neto A, Brown SM, Iwashyna TJ, Yealy DM, Hough CL, Brower RG, Calfee CS, Hyzy RC, Matthay MA, Miller RR, Steingrub JS, Thompson BT, Miller CD, Clemmer TP, Hendey GW, Huang DT, Mathews KS, Qadir N, Tidswell M. Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure. Ann Am Thorac Soc. 2019 03; 16(3):356-362.
Score: 0.028